Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin has filed a new drug submission (NDS) with the Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.
Subscribe to our email newsletter
Silenor could be the first and only prescription therapy for insomnia in Canada that is not a controlled substance, if approved.
Paladin has gained commercialization rights to Silenor in Canada, South America and Africa from Somaxon in June 2011.
Silenor is a low-dose (3mg and 6mg) oral tablet formulation of doxepin.
Paladin interim president and CEO Mark Beaudet said that Health Canada has accepted to review the company’s submission for Canadian regulatory approval for Silenor.
"We believe that Silenor can fill a significant unmet need in the Canadian insomnia market," Beaudet added.